Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Rhabdomyosarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Multiple Endocrine Neoplasia Type 2a 1 Medulloblastoma 1 Lethal Congenital Contracture Syndrome 2 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 9 Specimen Handling 7 X-Rays 6 Phantoms, Imaging 6 Nuclear Medicine Department, Hospital 5 Temozolomide 4 Biopsy 4 Vincristine 3 Cyclophosphamide 3 Cisplatin 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 selpercatinib 2 pembrolizumab 2 palbociclib 2 olaparib 2 lutetium Lu 177 dotatate 2 larotrectinib 2 ivosidenib 2 erdafitinib 2 ensartinib 2 Radiotherapy 2 Radiation 2 Platinum 2 Lomustine 2 LY3023414 2 Diphtheria-Tetanus Vaccine 2 1,2-diaminocyclohexaneplatinum II citrate 2 sodium thiosulfate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Medulloblastoma × Vascular Endothelial Growth Factor A × 90 days × Clear all

NCT07346157 2026-06-01

PNOC044

University of California, San Francisco

Phase 1/2 Not yet recruiting

Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡